NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch™ eTNS™ system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
"This conference represents an outstanding opportunity to put the Monarch in the hands of many healthcare professionals who will be future advocates of the system in the European Union. Our team looks forward to forming alliances and introducing a new paradigm for the management of epilepsy," said Leon Ekchian, Ph.D., NeuroSigma's President & CEO.
NeuroSigma was invited by the conference organizers to lead a Satellite Symposium on September 30th, focused on trigeminal nerve stimulation (TNS) for the treatment of epilepsy and neuropsychiatric disorders. The presentations on eTNS will cover the following topics:
- TNS Background Science
- Clinical Trials of eTNS for Drug Resistant Epilepsy
- Clinical Trials of eTNS for Depression and PTSD
- Monarch eTNS Product Launch in the European Union
The presenters will be Christopher DeGiorgio, M.D., NeuroSigma's Vice-President, Neurology, and Professor of Neurology at UCLA, Ian Cook, M.D., NeuroSigma Senior Medical Advisor and Professor of Psychiatry at UCLA and Colin Kealey, M.D., NeuroSigma's Manager of Business Development. The symposium will include the first public presentation of long-term data on the efficacy of eTNS for the treatment of epilepsy. Dr. DeGiorgio will also participate in an additional panel discussion, Devices and Epilepsy: the Future, on Wednesday, October 3rd.
NeuroSigma is preparing for a fourth quarter 2012 commercial launch of the Monarch in the European Union.
Gut-friendly psychobiotics could brighten moods and fight depression